BRIEF published on 05/05/2026 at 21:20, 5 months 25 days ago Neuvasq Showcases Promising Data at ARVO 2026 Therapeutic Potential Neuvasq Biotechnologies Blood-retina Barrier Gpr124-targeting Antibodies Retinal Vascular Diseases
PRESS RELEASE published on 05/05/2026 at 21:15, 5 months 25 days ago Neuvasq ARVO data Neuvasq Biotechnologies presents promising novel multispecific Gpr124-targeting antibodies for retinal diseases at ARVO 2026, demonstrating potential for new standards of care Retinal Diseases ARVO 2026 Neuvasq Biotechnologies Multispecific Antibodies Gpr124
Published on 10/30/2026 at 23:35, 12 hours 12 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 12 hours 17 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 16 hours 47 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 20 hours 17 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 12 hours 58 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 17 hours 9 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 18:35, 17 hours 12 minutes ago EQS-Adhoc: hep global GmbH expects to conclude refinancing negotiations only in fiscal year 2027
Published on 10/30/2026 at 23:00, 12 hours 47 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 17 hours 47 minutes ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 23 hours 47 minutes ago Capital increase through exercise of subscription rights
